Ad-hoc News

08.08.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presents key results of the extension phase of the exploratory phase Ib/IIa TEACH trial, a cooperation with the Aarhus University Hospital in...

22.04.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presents key results of the exploratory phase II IMPULSE study. The study was designed to evaluate efficacy and safety of the Company’s lead...

       

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com